AuraVax Therapeutics, Inc. (AuraVax) is a privately held biotechnology company
commercializing a new STING activation platform “NanoSTING” as an intranasal hostdirected-therapeutic for the treatment and prevention of upper respiratory
infections (URI) independent of the infecting pathogen(s).